tetano
Editor, Senior Moderator
J Microbiol Immunol Infect
. 2022 Aug 17;S1684-1182(22)00136-0.
doi: 10.1016/j.jmii.2022.08.007. Online ahead of print.
Clinical characteristics analysis of COVID-19 patients from the first significant community outbreak by SARS-CoV-2 variant B.1.1.7 in Taiwan as experienced from a single northern medical center
Ruei-Chang Huang[SUP] 1 [/SUP], Chun-Hsiang Chiu[SUP] 1 [/SUP], Hung-Sheng Shang[SUP] 2 [/SUP], Cherng-Lih Perng[SUP] 2 [/SUP], Tsung-Ta Chiang[SUP] 1 [/SUP], Chun-Chou Tsai[SUP] 1 [/SUP], Ching-Hsun Wang[SUP] 3 [/SUP]
Affiliations
Abstract
Background/purpose: Clinical characteristics of patients in the first community outbreak of coronavirus disease 2019 (COVID-19) by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variant B.1.1.7 in Taiwan have not been characterized.
Methods: SARS-CoV-2 positive specimens from inpatients between May 7 and June 15 in 2021were screen for SARS-CoV-2 B.1.1.7 lineage by VirSNiP assay. Clinical characteristics were reviewed and compared with those from Feb 1 to April 30, 2020 and from Jan 1 to March 31, 2022.
Results: One hundred forty-one inpatients from May 7 to June 15, 2021 infected with SARS-CoV-2 B.1.1.7 lineage were included. The major presenting symptoms were fever (88.7%) and cough (59.6%). Incidence of relevant complications including pulmonary embolism, simultaneous infections with bacteria, virus, and fungi were 0.7%, 12.8%, 13.5%, and 2.1%, respectively. Old age, high Charlson comorbidity index, short of breath, and initial critical illness were independently associated with 28-day mortality (all p < 0.05). In comparison to COVID-19 inpatients from Feb 1 to April 30, 2020, patients from the outbreak by SARS-CoV-2 B.1.1.7 lineage were older, more severe in disease condition, higher mortality but less obvious initial presenting symptoms. After implementation of nationwide vaccination campaign in the next half year of 2021, COVID-19 inpatients from Jan 1 to March 31 in 2022 indicated less severe diseases than those infected with SARS-CoV-2 B.1.1.7 lineage.
Conclusion: COVID-19 inpatients by SARS-CoV-2 variant B.1.1.7 with old age, multiple comorbidities, and more severe disease conditions were associated with increased mortality. Vaccination for this vulnerable populations may be helpful.
Keywords: B.1.1.529; B.1.1.7; COVID-19; Characteristics; SARS-COV-2; Taiwan.
. 2022 Aug 17;S1684-1182(22)00136-0.
doi: 10.1016/j.jmii.2022.08.007. Online ahead of print.
Clinical characteristics analysis of COVID-19 patients from the first significant community outbreak by SARS-CoV-2 variant B.1.1.7 in Taiwan as experienced from a single northern medical center
Ruei-Chang Huang[SUP] 1 [/SUP], Chun-Hsiang Chiu[SUP] 1 [/SUP], Hung-Sheng Shang[SUP] 2 [/SUP], Cherng-Lih Perng[SUP] 2 [/SUP], Tsung-Ta Chiang[SUP] 1 [/SUP], Chun-Chou Tsai[SUP] 1 [/SUP], Ching-Hsun Wang[SUP] 3 [/SUP]
Affiliations
- PMID: 36057491
- DOI: 10.1016/j.jmii.2022.08.007
Abstract
Background/purpose: Clinical characteristics of patients in the first community outbreak of coronavirus disease 2019 (COVID-19) by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variant B.1.1.7 in Taiwan have not been characterized.
Methods: SARS-CoV-2 positive specimens from inpatients between May 7 and June 15 in 2021were screen for SARS-CoV-2 B.1.1.7 lineage by VirSNiP assay. Clinical characteristics were reviewed and compared with those from Feb 1 to April 30, 2020 and from Jan 1 to March 31, 2022.
Results: One hundred forty-one inpatients from May 7 to June 15, 2021 infected with SARS-CoV-2 B.1.1.7 lineage were included. The major presenting symptoms were fever (88.7%) and cough (59.6%). Incidence of relevant complications including pulmonary embolism, simultaneous infections with bacteria, virus, and fungi were 0.7%, 12.8%, 13.5%, and 2.1%, respectively. Old age, high Charlson comorbidity index, short of breath, and initial critical illness were independently associated with 28-day mortality (all p < 0.05). In comparison to COVID-19 inpatients from Feb 1 to April 30, 2020, patients from the outbreak by SARS-CoV-2 B.1.1.7 lineage were older, more severe in disease condition, higher mortality but less obvious initial presenting symptoms. After implementation of nationwide vaccination campaign in the next half year of 2021, COVID-19 inpatients from Jan 1 to March 31 in 2022 indicated less severe diseases than those infected with SARS-CoV-2 B.1.1.7 lineage.
Conclusion: COVID-19 inpatients by SARS-CoV-2 variant B.1.1.7 with old age, multiple comorbidities, and more severe disease conditions were associated with increased mortality. Vaccination for this vulnerable populations may be helpful.
Keywords: B.1.1.529; B.1.1.7; COVID-19; Characteristics; SARS-COV-2; Taiwan.